Specialist
Dr Mark Specterman
Lips Healthcare Logo

Dr Mark Specterman

MBBS MRCP PhD

Cardiologist & Electrophysiologist

CardiologyElectrophysiologyPreventive CardiologyGeneral CardiologyHeart Failure

Reviews not available

120+
120+
Patients
7+
7+
Years Exp
4.95
4.95
LogoRating
100+
100+
Reviews

GMC: 6130970

About Dr Mark Specterman

Dr Mark Specterman is a Consultant Cardiologist & Electrophysiologist and Senior Lecturer at St George’s Hospital, London. He manages patients covering all areas of Cardiology but as a Cardiac Electrophysiologist, he is also a subspecialist in managing and treating patients with arrhythmias like SVT and AF (heart rhythm disturbances). He is also an expert in the management of patients with Inherited Cardiac Conditions and/or Family History of Sudden Death where he works as part of a world-renowned team at St George’s. This includes patients with cardiomyopathy (Hypertrophic Cardiomyopathy, Arrhythmogenic Cardiomyopathy, Dilated Cardiomyopathy) and ion channel disorders (Long QT Syndrome, Brugada Syndrome, Catecholaminergic Polmorphic VT). As part of this work Dr Specterman is co-chair of the South London Inherited Cardiac Conditions (SLICC) network. Dr Specterman completed medical training at Imperial College London in 2005 and went on to specialise in Cardiology and Cardiac Electrophysiology at The Essex Cardiothoracic Centre and Barts Heart Centre, London. His procedural expertise includes cardiac device implantation such as pacemakers and implantable cardioverter defibrillators (ICDs) together with ablation of arrhythmia. Dr Specterman was awarded a prestigious Medical Research Council Clinical Research Training Fellowship at Queen Mary, University of London and Barts Heart Centre London to investigate mechanisms and drug targets for atrial fibrillation via scientific laboratory-based techniques. He now continues research at St George’s, University of London alongside his clinical work. This research investigates the mechanisms of arrhythmia, cardiomyopathy (heart muscle disease) and inherited cardiac conditions in the search for new anti-arrhythmic therapies and methods of risk stratification of sudden death. As such he is at the forefront of world-leading treatment and research in this area of expertise.

Dr Mark Specterman Biography

Dr Mark Specterman is a Consultant Cardiologist & Electrophysiologist and Senior Lecturer at St George’s Hospital, London. He manages patients covering all areas of Cardiology but as a Cardiac Electrophysiologist, he is also a subspecialist in managing and treating patients with arrhythmias like SVT and AF (heart rhythm disturbances). He is also an expert in the management of patients with Inherited Cardiac Conditions and/or Family History of Sudden Death where he works as part of a world-renowned team at St George’s. This includes patients with cardiomyopathy (Hypertrophic Cardiomyopathy, Arrhythmogenic Cardiomyopathy, Dilated Cardiomyopathy) and ion channel disorders (Long QT Syndrome, Brugada Syndrome, Catecholaminergic Polmorphic VT). As part of this work Dr Specterman is co-chair of the South London Inherited Cardiac Conditions (SLICC) network. Dr Specterman completed medical training at Imperial College London in 2005 and went on to specialise in Cardiology and Cardiac Electrophysiology at The Essex Cardiothoracic Centre and Barts Heart Centre, London. His procedural expertise includes cardiac device implantation such as pacemakers and implantable cardioverter defibrillators (ICDs) together with ablation of arrhythmia. Dr Specterman was awarded a prestigious Medical Research Council Clinical Research Training Fellowship at Queen Mary, University of London and Barts Heart Centre London to investigate mechanisms and drug targets for atrial fibrillation via scientific laboratory-based techniques. He now continues research at St George’s, University of London alongside his clinical work. This research investigates the mechanisms of arrhythmia, cardiomyopathy (heart muscle disease) and inherited cardiac conditions in the search for new anti-arrhythmic therapies and methods of risk stratification of sudden death. As such he is at the forefront of world-leading treatment and research in this area of expertise.